MLTX vs. NFE

Last updated Jun 9, 2026

MLTX (MoonLake Immunotherapeutics) and NFE (New Fortress Energy Inc.) are both stocks. MLTX operates in Biotechnology (Healthcare), while NFE operates in Utilities - Regulated Gas (Utilities). Over the past 5 years, MLTX returned 12.25%/yr vs -56.82%/yr for NFE. At a 0.08 correlation, their price movements are largely independent.

Performance

MLTX vs. NFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MoonLake Immunotherapeutics (MLTX) and New Fortress Energy Inc. (NFE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MLTX achieves a 36.57% return, which is significantly higher than NFE's -53.99% return.

MLTX

• 1D: 0.56%
• 1M: 5.51%
• YTD: 36.57%
• 6M: 19.44%
• 1Y: -61.60%
• 3Y*: -14.95%
• 5Y*: 12.25%
• 10Y*: —

NFE

• 1D: 4.19%
• 1M: -25.07%
• YTD: -53.99%
• 6M: -62.80%
• 1Y: -82.34%
• 3Y*: -73.59%
• 5Y*: -56.82%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

MLTX vs. NFE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
MLTX MoonLake Immunotherapeutics	36.57%	-75.66%	-10.33%	475.14%	6.17%	-13.02%	8.39%
NFE New Fortress Energy Inc.	-53.99%	-92.46%	-59.24%	-1.71%	77.41%	-54.42%	3.58%

Correlation

The correlation between MLTX and NFE is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.04
Correlation (3Y) Calculated over the trailing 3-year period	0.09
Correlation (5Y) Calculated over the trailing 5-year period	0.08
Correlation (All Time) Calculated using the full available price history since Oct 21, 2020	0.08

Fundamentals

Market Cap MLTX : $1.28B NFE : $149.25M
EPS MLTX : -$3.90 NFE : -$6.58
PB Ratio MLTX : 5.05 NFE : 0.82
Total Revenue (TTM) MLTX : $0.00 NFE : $1.50B
Gross Profit (TTM) MLTX : -$1.49M NFE : $310.12M
EBITDA (TTM) MLTX : -$179.84M NFE : -$198.72M

Return for Risk

MLTX vs. NFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MLTX

MLTX Risk / Return Rank: 34
MLTX Sharpe Ratio Rank: 19
MLTX Sortino Ratio Rank: 49
MLTX Omega Ratio Rank: 63
MLTX Calmar Ratio Rank: 16
MLTX Martin Ratio Rank: 23

NFE

NFE Risk / Return Rank: 12
NFE Sharpe Ratio Rank: 15
NFE Sortino Ratio Rank: 12
NFE Omega Ratio Rank: 14
NFE Calmar Ratio Rank: 5
NFE Martin Ratio Rank: 14

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MLTX vs. NFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and New Fortress Energy Inc. (NFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MLTX	NFE	Difference
Sharpe ratio: Return per unit of total volatility	-0.53	-0.63	+0.10
Sortino ratio: Return per unit of downside risk	0.71	-0.98	+1.69
Omega ratio: Gain probability vs. loss probability	1.18	0.89	+0.29
Calmar ratio: Return relative to maximum drawdown	-0.69	-0.93	+0.24
Martin ratio: Return relative to average drawdown	-0.98	-1.24	+0.27
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MLTX vs. NFE - Sharpe Ratio Comparison

The current MLTX Sharpe Ratio is -0.53, which is comparable to the NFE Sharpe Ratio of -0.63. The chart below compares the historical Sharpe Ratios of MLTX and NFE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	MLTX	NFE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.53	-0.63	+0.10
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.14	-0.64	+0.77
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	-0.41	+0.53

Drawdowns

MLTX vs. NFE - Drawdown Comparison

The maximum MLTX drawdown since its inception was -90.22%, smaller than the maximum NFE drawdown of -99.09%. Use the drawdown chart below to compare losses from any high point for MLTX and NFE.

Drawdown Indicators

	MLTX	NFE	Difference
Max Drawdown Largest peak-to-trough decline	-90.22%	-99.09%	+8.87%
Max Drawdown (1Y) Largest decline over 1 year	-89.93%	-89.05%	-0.88%
Max Drawdown (3Y) Largest decline over 3 years	-90.22%	-98.72%	+8.50%
Max Drawdown (5Y) Largest decline over 5 years	-90.22%	-99.09%	+8.87%
Current Drawdown Current decline from peak	-71.81%	-99.04%	+27.23%
Average Drawdown Average peak-to-trough decline	-29.24%	-46.09%	+16.85%
Ulcer Index Depth and duration of drawdowns from previous peaks	63.21%	66.14%	-2.93%

Volatility

MLTX vs. NFE - Volatility Comparison

The current volatility for MoonLake Immunotherapeutics (MLTX) is 18.65%, while New Fortress Energy Inc. (NFE) has a volatility of 21.09%. This indicates that MLTX experiences smaller price fluctuations and is considered to be less risky than NFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MLTX	NFE	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.65%	21.09%	-2.44%
Volatility (6M) Calculated over the trailing 6-month period	55.24%	68.50%	-13.26%
Volatility (1Y) Calculated over the trailing 1-year period	115.84%	131.04%	-15.20%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.15%	89.68%	+1.47%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	86.45%	83.59%	+2.86%

Dividends

MLTX vs. NFE - Dividend Comparison

Neither MLTX nor NFE has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020
MLTX MoonLake Immunotherapeutics	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NFE New Fortress Energy Inc.	0.00%	0.00%	1.98%	10.46%	0.94%	1.66%	0.37%

Financials

Frequently Asked Questions

Can I hold both MLTX and NFE in my portfolio?

MLTX and NFE have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MLTX or NFE?

NFE has higher volatility (21.09%) compared to MLTX (18.65%). In terms of maximum drawdown, MLTX dropped -90.22% vs NFE's -99.09%.

Which has better risk-adjusted returns?

MLTX currently has the higher Sharpe Ratio (-0.53 vs -0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.